Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 1/20 | 0.53 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 2/20 | 0.44 |
| ▸ | CPB1 | P15086 | 1/20 | 0.44 |
| ▸ | CPA3 | P15088 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27807868 | 0.83 | KMT2A (0.42) | CYP2C19CYP2D6 | |
| SCHEMBL29239959 | 0.83 | ESR1 (0.43) | GABBR2GABBR1CYP2C19CYP2D6SRC | |
| SCHEMBL2655629 | 0.83 | CES2 (0.48) | GABBR2GABBR1CES2CES1CYP2D6 | |
| SCHEMBL22319291 | 0.83 | CES2 (0.48) | GABBR2GABBR1CES2CES1CYP2D6 | |
| SCHEMBL7470869 | 0.83 | CYP2C19 (0.51) | GABBR2GABBR1CES2CES1CYP2C19 | |
| SCHEMBL12473262 | 0.81 | GABBR2 (0.57) | GABBR2GABBR1CES2CES1CYP2C19 | |
| SCHEMBL7757013 | 0.81 | TSHR (0.57) | CES2CES1CYP2C19MAPTLMNA | |
| SCHEMBL28787354 | 0.81 | FFAR1 (0.49) | CYP2C19CYP2D6LMNAFFAR1 | |
| SCHEMBL27828421 | 0.81 | KMT2A (0.59) | GABBR2GABBR1CYP2C19CYP2D6LMNA | |
| SCHEMBL27782037 | 0.79 | HDAC4 (0.47) | CES2CES1MAPTMAPK1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-04 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| US-12295942-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-05-13 | — | — | US | disclosed |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-24 | — | — | US | disclosed |
| US-12213965-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-02-04 | — | — | US | disclosed |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-01-14 | — | — | US | disclosed |
| WO-1999059587-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999018099-A1 | ARYL THIOPHENE DERIVATIVES AS PDE IV INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 1999-04-15 | — | — | WO | disclosed |
| US-5137884-A | Antibiotics | MERCK & CO., INC. (US) | 1992-08-11 | — | — | US | disclosed |
| US-4501896-A | Phenylmercaptotetrazolo- and nitroindazolo masked development/image modifiers | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-02-26 | — | — | US | disclosed |
| US-4343893-A | RELEASED VIA ELECTRON TRANSFER | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-08-10 | — | — | US | disclosed |
| US-4238328-A | ADSORBENT COMPRISING POLYNITROGEN COMPOUND, A CARBOXYLIC ACID AND A CROSSLINKING COMPOUND | CIBA-GEIGY CORPORATION (US) | 1980-12-09 | — | — | US | disclosed |
| US-4144190-A | FOR HEAVY METAL IONS | CIBA-GEIGY AG (CH) | 1979-03-13 | — | — | US | disclosed |
| US-4024273-A | Coronary vasodilator and anti-anginal compositions comprising substituted benzofurans and benzothiophenes and methods of producing coronary vasodilation and anti-anginal activity | SMITHKLINE CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-3983245-A | CORONARY VASODILATORS | SMITHKLINE CORPORATION (US) | 1976-09-28 | — | — | US | disclosed |
| US-3947470-A | CORONARY VASODILATORS, TREATMENT OF ANGINA PECTORIS | SMITHKLINE CORPORATION (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | GABBR2 245/4885GABBR1 270/4885CES2 71/4885 |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | GABBR2 4000/4885GABBR1 4322/4885CES2 508/4885 |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | GABBR2 4000/4885GABBR1 4322/4885CES2 508/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | GABBR2 271/4885GABBR1 297/4885CES2 67/4885 |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | GABBR2 3850/4885GABBR1 4160/4885CES2 550/4885 |
| US-12472165-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | GABBR2 1917/4885GABBR1 1946/4885CES2 54/4885 |
| US-12295942-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | GABBR2 1917/4885GABBR1 1946/4885CES2 54/4885 |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | GABBR2 1917/4885GABBR1 1946/4885CES2 54/4885 |
| US-12213965-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | GABBR2 1917/4885GABBR1 1946/4885CES2 54/4885 |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | GABBR2 4000/4885GABBR1 4322/4885CES2 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.